South San Francisco, California, USA and Schlieren, Switzerland (ots) - AI genomics company Freenome announces partnership with leading proteomics company Biognosys to enhance its broad-signal approach to early-cancer detection and precision oncology. By decoding cell-free (cf) biomarker patterns of once unthinkable ...
EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Change of Personnel Kuros appoints Philippe Saudan as Chief Development Officer 10.08.2016 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. 490963 10.08.2016 ...
EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Research Update Kuros Biosciences AG: valuationLAB Initiates Research Coverage on Kuros 28.06.2016 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 474863 28.06.2016 ...
EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Miscellaneous First Trading Day of New Kuros Share after Reverse Split 23.06.2016 / 18:31 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 473985 23.06.2016 ...
EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): AGM/EGM Kuros Bioscience's Shareholders Approve All Resolutions 16.06.2016 / 14:38 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 472175 16.06.2016 ...
EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): AGM/EGM Kuros Biosciences Invites to the Annual Shareholders' Meeting 2016 26.05.2016 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 466703 26.05.2016 ...
EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Final Results Kuros Biosciences Reports Financial Results for 2015 26.04.2016 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 457559 26.04.2016 ...
EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Change of Personnel Kuros Biosciences Ltd. appoints Chief Medical Officer 08.03.2016 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 443197 08.03.2016 ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Mergers & Acquisitions Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd., constitutes its Board of Directors and appoints Executive Officers 08.01.2016 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): AGM/EGM Cytos Biotechnology AG: Extraordinary Shareholders' Meeting approves all resolutions 06.01.2016 / 12:05 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 427335 06.01.2016 ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): AGM/EGM Cytos Biotechnology Ltd. invites for an Extraordinary Shareholders' Meeting 15.12.2015 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 423509 15.12.2015 ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Merger Cytos Biotechnology and Kuros Biosurgery to combine to create Kuros Biosciences 03.12.2015 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 420717 03.12.2015 ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Agreement Cytos Biotechnology Ltd exclusively licenses its VLP platform for the treatment of Cancer to Checkmate Pharmaceuticals LLC 12.08.2015 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Half Year Results Cytos Biotechnology Ltd Reports the Financial Results of the First Half Year 2015 29.07.2015 / 17:30 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 382069 29.07.2015 ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): AGM/EGM Annual Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions 29.06.2015 / 14:38 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 373069 ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): AGM/EGM Cytos Biotechnology AG invites to the Annual General Meeting 08.06.2015 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 365761 08.06.2015 ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Bond Cytos Biotechnology AG: bond conversion into equity effective 08.05.2015 / 15:46 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 355233 08.05.2015 ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Financing Cytos Biotechnology AG will become debt-free 04.05.2015 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 352045 04.05.2015 ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Final Results Cytos Biotechnology Ltd Reports the Financial Results of 2014 28.04.2015 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 349321 28.04.2015 ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Bond Cytos Biotechnology AG: Extension of convertible bond listing at SIX Swiss Exchange 13.04.2015 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 343207 13.04.2015 ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Agreement Cytos Biotechnology AG: Novartis buys out CAD 106 license agreement for CHF 4 million 25.03.2015 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 336909 25.03.2015 ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): AGM/EGM Cytos Biotechnology AG: Extraordinary Shareholders' Meeting approves all resolutions 16.03.2015 / 11:12 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 333433 16.03.2015 ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Bond Cytos Biotechnology AG: The Higher Court of the Canton of Zurich approves the conversion of the convertible bonds into shares 13.03.2015 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): AGM/EGM Cytos Biotechnology AG: Invitation for an Extraordinary Shareholders' Meeting 19.02.2015 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 324605 19.02.2015 ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Miscellaneous Cytos Biotechnology AG: Bondholders' meeting approves conversion of bonds into shares with overwhelming majority 26.01.2015 / 14:23 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Miscellaneous Cytos Biotechnology AG: Trading of Cytos shares and convertible bonds temporarily suspended. 26.01.2015 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Financing Cytos Biotechnology Ltd updates on a key transaction and plans going forward 06.01.2015 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement. 310107 06.01.2015 ...
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Agreement Cytos Biotechnology AG exclusively licenses its VLP platform for the treatment of hepatitis B infections to OnCore Biopharma 06.01.2015 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content ...
Cytos Biotechnology AG / Key word(s): Change of Personnel 27.10.2014 18:00 Release of an ad hoc announcement pursuant to Art. 53 KR ...
Cytos Biotechnology AG / Key word(s): Half Year Results 30.09.2014 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR ...